Supplementary Figure S3 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial
Year: 2026
Type: supplementary-materials
Abstract: TME composition and evolutions in HER2+ and HER2- gastric cancer.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164987295
